Clinical Trial

The Relationship Between Serum S100B and Brain-Derived Neurotrophic Factor

Study acronym: S100B-BDNF
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 15, 2026 (before its estimated April 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Fibromyalgia is a chronic pain syndrome characterized by widespread musculoskeletal pain, fatigue, sleep disturbances, and cognitive symptoms. Central sensitization is considered a key mechanism in the pathophysiology of fibromyalgia; however, the underlying biological markers have not been fully clarified. Brain-derived neurotrophic factor (BDNF) and S100B protein have been suggested to play roles in neuroinflammation and central pain processing. This observational, cross-sectional study aims to evaluate serum S100B and BDNF levels in patients with fibromyalgia and to investigate their relationship with central sensitization and sleep quality. Serum biomarker levels and clinical assessment scales will be compared between patients with fibromyalgia and healthy controls.
Protocol Amendment History 1 change
critical Recruitment opened 2026-04-16
Trial Details
NCT Number NCT07358754
Lead Sponsor Kanuni Sultan Suleyman Training and Research Hospital
Conditions Fibromyalgia
Enrollment 60 participants
Start Date 2026-02-01
Primary Completion 2026-04-30 (estimated)
Study Completion 2026-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-15